Academician Ma Guanghui of the Chinese Academy of Sciences and His Delegation Visited Hybio Pharmaceutical to Explore the Development of Long-Acting High-Effect Innovative Peptide Formulations
On May 26, Academician Ma Guanghui from the Institute of Process Engineering of the Chinese Academy of Sciences (CAS), Deputy Director Yan Xuehai, and their delegation visited Hybio Pharmaceutical's Longhua headquarters. Both parties conducted in-depth exchanges on the application and development prospects of sustained-release microsphere long-acting technology in GLP-1 triple-target weight-loss peptides, as well as the application of peptide self-assembly technology in monthly formulations of high-effect innovative preparations such as lanreotide acetate. This visit marks a solid step forward in the integration and innovation of industry, academia, and research in the field of cutting-edge pharmaceutical preparations.
As an authoritative expert in China's biochemical engineering field, Academician Ma Guanghui has long focused on basic and engineering research in drug controlled release and carrier systems. Accompanied by Zeng Shaogui, Chairman and President of Hybio Pharmaceutical, Tang Yangming, Director and Vice President, other senior executives, and the R&D team, Academician Ma and his delegation visited the company's exhibition hall and R&D center, and had full exchanges on the application of the new generation of injectable sustained-release microsphere platforms in the treatment of metabolic diseases.
Chairman Zeng Shaogui highlighted the progress of the company's ongoing GLP-1R/GIPR/GCGR triple agonist project, which has entered the preclinical research stage. As a metabolic drug with an advanced mechanism of action, further improving patient convenience through long-acting formulation technology is a key research direction for Hybio Pharmaceutical. Academician Ma Guanghui then introduced the Institute of Process Engineering's years of accumulation in the research of complex pharmaceutical preparations, especially the breakthroughs achieved in the fields of self-assembled drug research and sustained-release microsphere technology. Academician Ma stated that the Institute of Process Engineering is willing to assist Hybio in overcoming key technical challenges such as poor uniformity of microsphere preparations, difficulty in scale-up, and basic research problems such as the difficulty in characterizing the self-assembly properties of lanreotide acetate through an "academia-enterprise cooperation" model, so as to accelerate the clinical transformation of scientific research results.
During the discussion, both parties also initially reached a consensus on cooperation mechanisms such as establishing a joint experimental platform and jointly promoting technical research projects. In the future, they will continue to carry out more in-depth strategic cooperation focusing on the R&D direction of long-acting peptide preparations and complex preparations. Hybio Pharmaceutical will continue to adhere to the development strategy of "innovation-led and cooperation-driven", and work with top domestic scientific research institutions to jointly explore solutions for the treatment of major chronic diseases such as obesity, diabetes, hyperlipidemia, and hypertension, contributing Hybio's strength to the cause of people's health.